VHH chain of nano antibody resisting FLAG tag and application of VHH chain
By developing the VHH chain of nano-antibody anti-FLAG tags, using alpaca immune and phage display technology, the problems of high production costs and poor stability of traditional antibodies are solved, high affinity and stability are achieved, suitable for a variety of experiments, and widen the application prospect.
Patent Information
- Application Number
- CN202310582992.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-22
- Publication Date
- 2024-11-22
AI Technical Summary
The production cost and poor stability of existing anti-FLAG-tagged antibodies limit their application in basic scientific research and clinical research. Traditional antibodies have low expression yields and low solubleness in microbial systems, which can easily form aggregates, resulting in batch unstable .
The VHH chain of an anti-FLAG-tagged nanobody was developed, including framework region FR and heavy chain variable region CDR. The high affinity amino acid sequence was screened through alpaca immune and phage display technology, achieving high affinity in E. coli and yeast. It is expressed in a stable mass and is covalently coupled on agarose beads or magnetic beads, avoiding interference from traditional antibodies light and heavy chains.
The high affinity, stability and easy production of anti-FLAG-tagged nano-antibody has been achieved, with a small batch difference and still maintaining more than 95% activity for two weeks at room temperature. It is suitable for the isolation and purification, immunoprecipitation and ELISA experiments of FLAG-tagged proteins. Broaden its application prospects.
Smart Images

Figure CN118994405A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of immunotechnology, and in particular to a VHH chain of an anti-FLAG tag nano antibody and an application thereof. Background Art
[0002] The FLAG tag is the first epitope tag designed for fusion proteins. It consists of 8 amino acids (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) and has a molecular weight of 1012Da. The FLAG tag usually does not affect the activity of the target protein and is widely used for immunoadsorption and purification of the target protein. In addition, the FLAG tag is also widely used in a variety of immunoassays for target proteins. If there is no antibody against the target protein, after the target protein is fused with the FLAG tag, the Flag tag antibody can be used to study the target protein, such as western blot, ELISA (enzyme linked immunosorbent assay) and IP (Immunoprecipitation) experiments. Therefore, FLAG tag antibodies have broad application prospects.
[0003] Currently, commercialized anti-FLAG tag antibodies are mainly traditional antibodies, which are tetramers composed of two heavy chains and two light chains with a molecular weight of about 150KDa. Traditional antibodies have high specificity and high affinity for antigens, but they have large molecular weights, complex production processes, unstable batches, and are relatively expensive. Therefore, the application of anti-FLAG tag antibodies in basic scientific research and clinical research is severely limited. Although genetic engineering technology can be used to prepare antigen-binding fragments of traditional antibodies into antibodies with smaller molecular weights, such as Fab (antigen-binding fragment, about 50KDa) and scFV (single chain variable fragment, about 25KDa), such antibodies have low yields when expressed in microbial systems, low solubility, poor stability, and are prone to aggregate formation. Therefore, the widespread application of such antibodies is still limited.
[0004] Nanobodies are the variable domains of natural heavy chain antibodies. The heavy chain antibodies were first isolated from camel serum in 1993, and were subsequently found in alpacas, llamas and other camelids, as well as cartilaginous fish such as nurse sharks. Heavy chain antibodies are special antibodies composed of only two heavy chains. Camel heavy chain antibodies contain only one heavy chain variable region (VHH, Variable Domain of Heavy Chain Antibody) and two conventional CH2 and CH3 regions. Heavy chain antibodies specifically bind antigens through a variable region (VHH) on the heavy chain. This variable region can exist stably in vitro alone and is called a nanobody. Nanobodies are the smallest naturally occurring structures with complete antigen recognition capabilities. Their crystals are 4nm long, 2.5nm wide, and their molecular weight is only one-tenth of that of traditional complete antibodies (12-15KD). Thanks to the high antigen affinity, small molecular weight, high stability, high specificity, strong penetration, and easy transformation and expression of nanobodies, nanobodies can be produced stably and with high quality through in vitro recombinant expression, effectively avoiding the batch-to-batch differences of traditional antibodies. These advantages will enhance and broaden the application of nanoantibodies in basic research, and are expected to enable widespread use of nanoantibodies in diagnosis and clinical treatment.
[0005] Commercial anti-FLAG tag antibodies are all traditional antibodies, which often have problems such as high production costs and poor stability, which are not conducive to the application of anti-FLAG tag antibodies. Since nano antibodies can be expressed in high quality and stable manner in microorganisms such as Escherichia coli and yeast, they can overcome many defects of traditional antibodies, so anti-FLAG tag nano antibodies have broad application prospects.
[0006] Therefore, the prior art has defects and needs to be improved. Summary of the invention
[0007] The technical problem to be solved by the present invention is to provide a VHH chain of an anti-FLAG tag nanobody and an application thereof, so as to provide support for the application of the anti-FLAG tag nanobody.
[0008] The technical solution of the present invention is as follows: a VHH chain of an anti-FLAG tag nanobody is provided, comprising: a framework region FR and a heavy chain variable region CDR; the heavy chain variable region CDR comprises: CDR1, CDR2 and CDR3; the framework region FR comprises FR1, FR2, FR3 and FR4, specifically arranged as: FR1, CDR1, FR2, CDR2, FR3, CDR1, FR4; the specific amino acid sequence is as follows: CDR1 is SEQ ID NO: 1, CDR2 is SEQ ID NO: 2, CDR3 is SEQ ID NO: 3, FR1 is SEQ ID NO: 4, FR2 is SEQ ID NO: 5, FR3 is SEQ ID NO: 6, and FR4 is SEQ ID NO: 7.
[0009] The present invention provides a VHH chain of an anti-FLAG tag nanobody, whose amino acid sequence is shown in SEQ ID NO:8.
[0010] The present invention also provides an anti-FLAG tag nanobody, which includes any one of the amino acid sequences having 95% or more identity with the amino acid sequence shown in the aforementioned SEQ ID NO: 8, or having no more than five amino acid mutations compared with the amino acid sequence shown in the aforementioned SEQ ID NO: 8.
[0011] The present invention provides an anti-FLAG tag nanobody, whose CDR1 includes any one amino acid sequence that has 90% or more identity with the amino acid sequence shown in SEQ ID NO:1, or has one or two amino acid mutations compared with the amino acid sequence shown in SEQ ID NO:1.
[0012] The present invention provides an anti-FLAG tag nanobody, whose CDR2 includes any one of the amino acid sequences having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 2, or has one or two amino acid mutations compared with the amino acid sequence shown in SEQ ID NO: 2.
[0013] The present invention provides an anti-FLAG tag nanobody, whose CDR3 includes any one amino acid sequence that has 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3, or has one or two amino acid mutations compared with the amino acid sequence shown in SEQ ID NO: 3.
[0014] The present invention also provides a gene sequence, which encodes the VHH chain of the aforementioned anti-FLAG tag nanobody or encodes the aforementioned anti-FLAG tag nanobody.
[0015] By adopting the above scheme, the present invention provides a VHH chain of an anti-FLAG tag nano antibody and its application, the anti-FLAG tag nano antibody is easy to produce and has a small batch difference; it can still maintain more than 95% activity after being stored at room temperature for two weeks, and has good stability; the anti-FLAG tag nano antibody can be covalently coupled to agarose beads or magnetic beads for use, effectively avoiding the problem of interference between light and heavy chains of traditional antibodies in IP experiments. In summary, the anti-FLAG tag nano antibody has broad application prospects in experiments such as separation and purification, immunoprecipitation, co-immunoprecipitation, and ELISA of proteins fused with FLAG tags. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 This is the affinity test curve of the anti-FLAG tag nanobody of the present invention and FLAG;
[0017] Figure 2 The results of immunoprecipitation experiments using SDS-PAGE were performed on the anti-FLAG tag nanobody of the present invention. DETAILED DESCRIPTION
[0018] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments.
[0019] This embodiment develops alpaca nanoantibodies with high affinity for FLAG tags, which can achieve specific capture of FLAG tag fusion proteins and can be applied to WB, ELISA, IP, CO-IP, MS and other experiments of FLAG tag fusion proteins. The specific research and development method of FLAG tag is: use FLAG short peptide (DYKDDDDK) fused with KLH (Keyhole Limpet Haemocyanin, hemocyanin) as antigen to immunize alpacas, 500μg each time, a total of four immunizations, once every two weeks; draw 5mL of peripheral blood before each immunization, and draw 5mL of peripheral blood 5 to 7 days after the fourth immunization, a total of five peripheral blood draws; separate the serum of five tubes of peripheral blood, and perform serum titer detection. When the serum is diluted 105, the OD450 value is still higher than 0.5, indicating that the serum titer meets the standard; draw 50mL of alpaca peripheral blood, extract PBMC by density gradient centrifugation, and 10mL After washing twice with PBS, the PBMCs were stored in Trizol; total RNA from 50 mL of peripheral blood PBMCs was extracted, and the quality of the extracted total RNA was confirmed by agarose gel; all the extracted RNA was reverse transcribed to obtain cDNA, and the cDNA was used as a template to obtain a DNA library containing the nanobody sequence through two rounds of PCR; it was connected to the phagemid and electroporated into TG1 Escherichia coli to obtain a bacterial library; the library capacity, clone positive rate and diversity of the bacterial library were measured; the helper phage was used for infection, and then two rounds of phage panning were used to enrich the phages that specifically bind to the FLAG tag; a number of (in this embodiment, 384) single clones were picked, and two rounds of Elisa verification were performed. Positive clones (OD450>0.5) were sequenced by Sanger sequencing, and a total of several (in this embodiment, 5) independent non-repetitive positive sequences were obtained; Pichia pastoris was used for expression and purification, and the affinity was detected by Elisa, and it was found that the affinity of the sequence VHH to the FLAG peptide reached the nanomolar level, and it was prepared into a bivalent antibody. At this point, a FLAG-tagged nanobody was successfully obtained, and it was further applied to the purification, IP, Co-IP, ELISA and other experiments of FLAG-tagged fusion proteins, solving the problems of traditional monoclonal antibodies being difficult to purify, large batch differences, high production costs, not conducive to subsequent modification and transformation, and easy to cause light and heavy chain interference in IP or Co-IP experiments.
[0020] The VHH chain of the anti-FLAG tag Nanobody of the present invention comprises three heavy chain variable regions: CDR1, CDR2 and CDR3, and four framework regions: FR1, FR2, FR3 and FR4.
[0021] CDR1 includes the amino acid sequence shown in SEQ ID NO: 1: GRSLGRYA;
[0022] CDR2, which includes the amino acid sequence shown in SEQ ID NO:2: INNGGKT;
[0023] CDR3, which includes the amino acid sequence shown in SEQ ID NO:3: AARTPRVGALLSTSLTYDY;
[0024] FR1, which includes the amino acid sequence shown in SEQ ID NO:4: DVQLQESGGGLALVGGSLRLSCADS;
[0025] FR2, which includes the amino acid sequence shown in SEQ ID NO:5: VAWFRQAPGKERELVTR;
[0026] FR3, which includes the amino acid sequence shown in SEQ ID NO:6: TYADSVKGRFAISRDNAKNMVYLQMNNLKPEDTAVYFC;
[0027] FR4 comprises the amino acid sequence shown in SEQ ID NO:7: WGQGTQVTVSS.
[0028] This example also provides a VHH chain of an anti-FLAG tag nanobody, whose amino acid sequence is shown in SEQ ID NO: 8: DVQLQESGGGLALVGGSLRLSCADSGRSLGRYAVAWFRQAPGKERELV TRINNGGGKTTYADSVKGRFAISRDNAKNMVYLQMNNLKPEDTAVYFC AARTPRVGALLSTSLTYDYWGQGTQVTVSS.
[0029] This embodiment also provides an anti-Flag tag nanobody, which includes any one of the amino acid sequences having 95% or more identity with the amino acid sequence shown in the aforementioned SEQ ID NO: 8, or having no more than five amino acid mutations compared with the amino acid sequence shown in the aforementioned SEQ ID NO: 8.
[0030] The anti-Flag tag Nanobody, wherein the heavy chain variable region CDR1 includes any one amino acid sequence that has 90% or more identity with the amino acid sequence shown in SEQ ID NO:1, or has one or two amino acid mutations compared to the amino acid sequence shown in SEQ ID NO:1.
[0031] The anti-Flag tag Nanobody, wherein the heavy chain variable region CDR2 includes any one amino acid sequence that has 90% or more identity with the amino acid sequence shown in SEQ ID NO: 2, or has one or two amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 2.
[0032] The anti-Flag tag Nanobody, wherein the heavy chain variable region CDR3 includes any one amino acid sequence that has 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3, or has one or two amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 3.
[0033] The present invention also provides a gene sequence, which encodes the VHH chain of the aforementioned anti-FLAG tag nanobody or encodes the aforementioned anti-FLAG tag nanobody.
[0034] Example 1
[0035] Anti-FLAG tag nanobody expression and purification
[0036] The gene of anti-FLAG tag nanobody was electroporated into Pichia pastoris, secretory expression was induced, and the supernatant was collected and purified using Ni column and molecular sieve column respectively. 5 mg of anti-FLAG tag nanobody was obtained from 200 mL of culture medium.
[0037] The present invention uses the alpaca immunization method to construct an immune library, screens the amino acid sequence library of anti-FLAG tag nano antibodies through phage display technology, and obtains anti-FLAG tag bivalent nano antibodies through further artificial modification and optimization. Figure 1 It can be seen that the affinity of the anti-FLAG tag nanobody disclosed in the present invention to FLAG reaches 1.72 nM.
[0038] Comparative Example 1
[0039] Anti-FLAG tag traditional monoclonal antibody (antibody species: Mouse antibody subclass IgG1) was expressed and purified.
[0040] Hek293 cells (200 mL culture medium) were transfected with a plasmid of a conventional monoclonal antibody against the FLAG tag. After 24 hours, the cells were collected by centrifugation, lysed with a lysis buffer containing a protease inhibitor, and the supernatant was collected. After Protein A affinity chromatography, 500 μg of anti-FLAG tag monoclonal antibody was obtained from 200 mL culture medium.
[0041] In comparison, nanobodies can be expressed and purified using microorganisms, while traditional antibodies need to be expressed and purified using mammalian cells, which has higher culture costs. Moreover, for the same culture medium volume, the anti-FLAG tag traditional monoclonal antibodies purified from mammalian cells have less mass and lower molar concentration.
[0042] Test experiment on the anti-FLAG tag nanobody obtained in Example 1
[0043] Anti-FLAG tag nanoantibody magnetic bead immunoprecipitation experiment
[0044] 1. Collect cells expressing FLAG-tagged protein: Collect 106-107 mammalian cells expressing Flag fusion protein, centrifuge at 1200G for 3 minutes at 4℃, discard the supernatant, resuspend the cells in 1XPBS precooled to 4℃, centrifuge, discard the supernatant, and repeat twice.
[0045] 2. Lyse cells:
[0046] ① Resuspend the cells with 200μL pre-cooled Lysis buffer (containing protease inhibitors and 1mM PMSF); ② Place the centrifuge tube on ice for 30-40 minutes, and resuspend the cells every 10 minutes; ③ Centrifuge at 4℃, 12000G for 10 minutes, transfer the supernatant to a new pre-cooled centrifuge tube, add 300μL 1XPBS, and discard the precipitate.
[0047] 3. Balance the magnetic beads:
[0048] ① Vortex Anti-Flag VHH Magarose Beads, pipette 25 μL (including suspension) into a 1.5 mL centrifuge tube; ② Add 1 mL 1xPBST (0.05% Tween-20), shake up and down for 60 seconds by hand, not too violently; ③ Place on a magnetic stand and let stand for 60 seconds to separate the magnetic beads until the supernatant is clear, discard the supernatant, and repeat 3 times.
[0049] 4. Binding protein:
[0050] ① Add the cell protein extract obtained in step 2 to the balanced magnetic beads; ② Rotate on a rocking table at 4°C for 2 hours.
[0051] 5. Washing
[0052] ① Use a magnetic rack to separate the magnetic beads until the supernatant is clear and discard the supernatant; ② Add 1 ml 1xPBST (0.05% Tween-20) to suspend the magnetic beads; ③ Use a magnetic rack to separate the magnetic beads and discard the supernatant. Repeat this step at least 4 times.
[0053] 6. Elute the bound protein
[0054] ① Remove the remaining supernatant, add 50-70μL 0.2M, pH 2.5 glycine, and mix at 4℃ for 5 minutes; ② Use a magnetic stand to separate the magnetic beads, transfer the supernatant to another EP tube, and immediately neutralize the eluent with 25-35μL 1M, pH 10.4 Tris solution. Repeat the above steps ① and ② to increase the elution efficiency.
[0055] 7. SDS-PAGE detection of immunoprecipitation results
[0056] Take 10 μL of the FLAG tag fusion protein eluate obtained in the above steps from each tube and run the gel to detect the purity, concentration and apparent molecular weight of the protein pulled by the immunoprecipitation experiment. Figure 2 .
[0057] The conventional anti-FLAG tag monoclonal antibody obtained in Comparative Example 1 was tested
[0058] Traditional anti-FLAG tag monoclonal antibody magnetic bead immunoprecipitation experiment
[0059] The steps of collecting, lysing cells and balancing magnetic beads are the same as steps 1, 2 and 3 above. In the protein binding process in step 4, agarose beads coupled to Protein G, anti-FLAG tag monoclonal antibody and protein extract are mixed and rotated on a rocking table at 4°C for 4 hours. The steps of washing, eluting bound proteins and SDS-PAGE detection are the same as steps 5 to 7 above.
[0060] Comparing the operation process of nano antibody magnetic beads and monoclonal antibody magnetic beads, it can be seen that the time required for nano antibody to bind to FLAG tag fusion protein is shorter; Figure 2 It can be seen that nano antibodies have no interference from light and heavy chains in IP experiments, and the experimental results are simpler and more intuitive.
[0061] In summary, the present invention provides a VHH chain of an anti-FLAG tag nanobody and its application. The anti-FLAG tag nanobody is easy to produce and has a small batch-to-batch difference. It can still maintain more than 95% activity after being stored at room temperature for two weeks and has good stability. The anti-FLAG tag nanobody can be covalently coupled to agarose beads or magnetic beads for use, effectively avoiding the problem of interference between light and heavy chains of traditional antibodies in IP experiments. In summary, the anti-FLAG tag nanobody has broad application prospects in experiments such as separation and purification of proteins fused with FLAG tags, immunoprecipitation, co-immunoprecipitation, ELISA, etc.
[0062] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A VHH chain of an anti-FLAG tag nanobody, characterized in that include: Framework region FR and heavy chain variable region CDR; heavy chain variable region CDR includes: CDR1, CDR2 and CDR3; framework region FR includes FR1, FR2, FR3 and FR4, specifically arranged as: FR1, CDR1, FR2, CDR2, FR3, CDR1, FR4; the specific amino acid sequence is as follows: CDR1 is SEQ ID NO: 1, CDR2 is SEQ ID NO: 2, CDR3 is SEQ ID NO: 3, FR1 is SEQ ID NO: 4, FR2 is SEQ ID NO: 5, FR3 is SEQ ID NO: 6, and FR4 is SEQ ID NO:
7.
2. The VHH chain of an anti-FLAG tag nanobody according to claim 1, characterized in that: Its amino acid sequence is shown in SEQ ID NO:
8.
3. A nanobody against FLAG tag, characterized in that: It includes any amino acid sequence that has 95% or more identity with the amino acid sequence shown in SEQ ID NO: 8 in claim 2, or has no more than five amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 8 in claim 2.
4. The anti-FLAG tag nanobody according to claim 3, characterized in that: Its CDR1 includes any one of the amino acid sequences having 90% or more identity with the amino acid sequence shown in SEQ ID NO:1, or having one or two amino acid mutations compared with the amino acid sequence shown in SEQ ID NO:
1.
5. The anti-FLAG tag nanobody according to claim 3, characterized in that: Its CDR2 includes any one of the amino acid sequences having 90% or more identity with the amino acid sequence shown in SEQ ID NO:2, or having one or two amino acid mutations compared with the amino acid sequence shown in SEQ ID NO:
2.
6. The anti-FLAG tag nanobody according to claim 3, characterized in that: Its CDR3 includes any one of the amino acid sequences having 90% or more identity with the amino acid sequence shown in SEQ ID NO:3, or has one or two amino acid mutations compared with the amino acid sequence shown in SEQ ID NO:
3.
7. A gene sequence, characterized in that It encodes the VHH chain of the anti-FLAG tag Nanobody as described in claim 1 or 2, or it encodes the anti-FLAG tag Nanobody as described in claim 3 or 4 or 5 or 6.
